{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:08Z","timestamp":1791357188335,"version":"4.3.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2012,5,4]],"date-time":"2012-05-04T00:00:00Z","timestamp":1336089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0036476","type":"journal-article","created":{"date-parts":[[2012,5,4]],"date-time":"2012-05-04T18:40:38Z","timestamp":1336156838000},"page":"e36476","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":149,"title":["Duloxetine Inhibits Effects of MDMA (\u201cEcstasy\") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00990067","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"C\u00e9dric M.","family":"Hysek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda D.","family":"Simmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina G.","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerina","family":"Vischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Grouzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Huwyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius C.","family":"Hoener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The molecular mechanism of \u201cecstasy&quot; [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.","volume":"89","author":"G Rudnick","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.","volume":"39","author":"RB Rothman","year":"2001","journal-title":"Synapse"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","article-title":"MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.","volume":"189","author":"CD Verrico","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref4","first-page":"544","article-title":"Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux.","volume":"47","author":"SC Wall","year":"1995","journal-title":"Mol Pharmacol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/(SICI)1098-2396(20000301)35:3<222::AID-SYN7>3.0.CO;2-K","article-title":"Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse.","volume":"35","author":"RB Rothman","year":"2000","journal-title":"Synapse"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/syn.20804","article-title":"Evidence for noncompetitive modulation of substrate-induced serotonin release.","volume":"64","author":"RB Rothman","year":"2010","journal-title":"Synapse"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","article-title":"Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy&quot;) are attenuated by the serotonin uptake inhibitor citalopram.","volume":"22","author":"ME Liechti","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","article-title":"The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.","volume":"189","author":"M Tancer","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.107.129056","article-title":"Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.","volume":"323","author":"M Farre","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","article-title":"The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy&quot;) in humans.","volume":"90","author":"CM Hysek","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3109\/00952990903383961","article-title":"Atomoxetine attenuates dextroamphetamine effects in humans.","volume":"35","author":"M Sofuoglu","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/jpet.111.188425","article-title":"Effects of the \u03b1<sub>2<\/sub>-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of methylenedioxymethamphetamine in healthy volunteers.","volume":"340","author":"CM Hysek","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.","volume":"25","author":"FP Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1517\/13543784.7.10.1691","article-title":"Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate.","volume":"7","author":"DT Wong","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"ref15","first-page":"649","article-title":"Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.","volume":"44","author":"M Segura","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Duloxetine: clinical pharmacokinetics and drug interactions.","volume":"50","author":"MP Knadler","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","article-title":"Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites.","volume":"149","author":"G Battaglia","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"ref18","article-title":"SKID-I: Strukturiertes Klinisches Interview f\u00fcr DSM-IV.","author":"HU Wittchen","year":"1997"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1192\/bjp.128.3.280","article-title":"The SCL-90 and the MMPI: a step in the validation of a new self-report scale.","volume":"128","author":"LR Derogatis","year":"1976","journal-title":"Br J Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1008931926181","article-title":"The Symptom Check-List-90-R (SCL-90-R): a German validation study.","volume":"9","author":"N Schmitz","year":"2000","journal-title":"Qual Life Res"},{"key":"ref21","article-title":"Die Eigenschaftsw\u00f6rterliste.","author":"W Janke","year":"1978"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.","volume":"S2","author":"A Dittrich","year":"1998","journal-title":"Pharmacopsychiatry 31"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV).","volume":"5","author":"E Studerus","year":"2010","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","article-title":"Human pharmacology of 3,4-methylenedioxymethamphetamine (\u201cecstasy&quot;): psychomotor performance and subjective effects.","volume":"20","author":"J Cami","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/JCP.0b013e31817ef470","article-title":"Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.","volume":"28","author":"EA Kolbrich","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref26","article-title":"Die Beschwerden-Liste.","author":"DV Zerssen","year":"1976"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1210\/jc.2011-1143","article-title":"Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects.","volume":"96","author":"LD Simmler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","article-title":"Pharmacological profile of antidepressants and related compounds at human monoamine transporters.","volume":"340","author":"M Tatsumi","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.","volume":"22","author":"Y Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"ref30","first-page":"1144","article-title":"Transport of the \u03b2-lactam antibiotic benzylpenicillin and the dipeptide glycylsarcosine by brain capillary endothelial cells in vitro.","volume":"26","author":"M Torok","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/npp.1993.19","article-title":"Psychological effects of MDE in normal subjects: are entactogens a new class of psychoactive agents?","volume":"8","author":"L Hermle","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.biopsych.2010.08.003","article-title":"Is ecstasy an \u201cempathogen&quot;? Effects of\u00b13,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.","volume":"68","author":"G Bedi","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.24895","article-title":"Oral cocaine: plasma concentrations and central effects.","volume":"200","author":"C Van Dyke","year":"1978","journal-title":"Science"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.105.084426","article-title":"Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters.","volume":"314","author":"C Pifl","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2210-6-6","article-title":"Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.","volume":"6","author":"DD Han","year":"2006","journal-title":"BMC Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2003.08.054","article-title":"Monoamine transporters and psychostimulant drugs.","volume":"479","author":"RB Rothman","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1073\/pnas.0407737102","article-title":"Amphetamine induces dopamine efflux through a dopamine transporter channel.","volume":"102","author":"KM Kahlig","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1073\/pnas.110035297","article-title":"Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.","volume":"97","author":"C Saunders","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12035-009-8053-4","article-title":"A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.","volume":"39","author":"SD Robertson","year":"2009","journal-title":"Mol Neurobiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1523\/JNEUROSCI.4574-09.2010","article-title":"Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking.","volume":"30","author":"HJ Matthies","year":"2010","journal-title":"J Neurosci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1074\/jbc.M109.093658","article-title":"Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylenedioxymethamphetamine.","volume":"285","author":"JR Field","year":"2010","journal-title":"J Biol Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1073\/pnas.1011920108","article-title":"Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.","volume":"108","author":"BJ Thompson","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pbb.2008.02.018","article-title":"Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.","volume":"90","author":"MH Baumann","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0269881107083639","article-title":"MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine\/norepinephrine transport inhibitor.","volume":"22","author":"CD Verrico","year":"2008","journal-title":"J Psychopharmacol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0924-977X(00)00086-9","article-title":"Acute psychological and physiological effects of MDMA (\u201cEcstasy&quot;) after haloperidol pretreatment in healthy humans.","volume":"10","author":"ME Liechti","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.clinthera.2009.05.005","article-title":"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.","volume":"31","author":"RK Zhao","year":"2009","journal-title":"Clin Ther"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuropharm.2011.03.028","article-title":"High concentrations of MDMA (\u201cecstasy&quot;) and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells.","volume":"61","author":"L Hondebrink","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0014-2999(94)90669-6","article-title":"Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT<sub>2<\/sub> receptor agonists.","volume":"264","author":"GA Gudelsky","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1471-4159.1996.66010243.x","article-title":"Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions.","volume":"66","author":"GA Gudelsky","year":"1996","journal-title":"J Neurochem"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.biopsych.2006.02.029","article-title":"Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain.","volume":"61","author":"GG Gould","year":"2007","journal-title":"Biol Psychiatry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0036476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T17:44:24Z","timestamp":1539971064000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0036476"}},"subtitle":[],"editor":[{"given":"Jerson","family":"Laks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,4]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0036476","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,4]]}}}